Breakthrough business models: drug development for rare and neglected diseases and individualized therapies : workshop summary
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
National Academies Press
2009
|
| Schlagworte: | |
| Beschreibung: | Includes bibliographical references (p. 104-105) |
| Beschreibung: | 149 p. |
| ISBN: | 9780309120883 0309120888 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044108907 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2009 |||| o||u| ||||||eng d | ||
| 020 | |a 9780309120883 |9 978-0-309-12088-3 | ||
| 020 | |a 0309120888 |9 0-309-12088-8 | ||
| 035 | |a (ZDB-30-PAD)EBC3378464 | ||
| 035 | |a (ZDB-89-EBL)EBL3378464 | ||
| 035 | |a (OCoLC)311565225 | ||
| 035 | |a (DE-599)BVBBV044108907 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 362.17820973 |2 22 | |
| 245 | 1 | 0 | |a Breakthrough business models |b drug development for rare and neglected diseases and individualized therapies : workshop summary |c Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, D.C. |b National Academies Press |c 2009 | |
| 300 | |a 149 p. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references (p. 104-105) | ||
| 650 | 4 | |a Politik | |
| 650 | 4 | |a Orphan drugs |x Government policy |z United States | |
| 650 | 4 | |a Pharmaceutical policy |z United States | |
| 650 | 4 | |a Drugs |x Design |z United States | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Wizemann, Theresa M. |e Sonstige |4 oth | |
| 700 | 1 | |a Robinson, Sally |e Sonstige |4 oth | |
| 700 | 1 | |a Giffin, Robert B. |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.)XXbForum on Drug Discovery, Development, and Translation |e Sonstige |4 oth | |
| 912 | |a ZDB-30-PAD |a ZDB-30-PBE | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029515752 | ||
Datensatz im Suchindex
| _version_ | 1804177182629560323 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV044108907 |
| collection | ZDB-30-PAD ZDB-30-PBE |
| ctrlnum | (ZDB-30-PAD)EBC3378464 (ZDB-89-EBL)EBL3378464 (OCoLC)311565225 (DE-599)BVBBV044108907 |
| dewey-full | 362.17820973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.17820973 |
| dewey-search | 362.17820973 |
| dewey-sort | 3362.17820973 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01590nmm a2200409zc 4500</leader><controlfield tag="001">BV044108907</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309120883</subfield><subfield code="9">978-0-309-12088-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309120888</subfield><subfield code="9">0-309-12088-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC3378464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL3378464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)311565225</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044108907</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.17820973</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Breakthrough business models</subfield><subfield code="b">drug development for rare and neglected diseases and individualized therapies : workshop summary</subfield><subfield code="c">Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">149 p.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (p. 104-105)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Politik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orphan drugs</subfield><subfield code="x">Government policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield><subfield code="z">United States</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wizemann, Theresa M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, Sally</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giffin, Robert B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)XXbForum on Drug Discovery, Development, and Translation</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield><subfield code="a">ZDB-30-PBE</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029515752</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV044108907 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:43:54Z |
| institution | BVB |
| isbn | 9780309120883 0309120888 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029515752 |
| oclc_num | 311565225 |
| open_access_boolean | |
| physical | 149 p. |
| psigel | ZDB-30-PAD ZDB-30-PBE |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies Washington, D.C. National Academies Press 2009 149 p. txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references (p. 104-105) Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs Design United States USA Wizemann, Theresa M. Sonstige oth Robinson, Sally Sonstige oth Giffin, Robert B. Sonstige oth Institute of Medicine (U.S.)XXbForum on Drug Discovery, Development, and Translation Sonstige oth |
| spellingShingle | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs Design United States |
| title | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary |
| title_auth | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary |
| title_exact_search | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary |
| title_full | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Breakthrough business models drug development for rare and neglected diseases and individualized therapies : workshop summary Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Breakthrough business models |
| title_sort | breakthrough business models drug development for rare and neglected diseases and individualized therapies workshop summary |
| title_sub | drug development for rare and neglected diseases and individualized therapies : workshop summary |
| topic | Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs Design United States |
| topic_facet | Politik Orphan drugs Government policy United States Pharmaceutical policy United States Drugs Design United States USA |
| work_keys_str_mv | AT wizemanntheresam breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT robinsonsally breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT giffinrobertb breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary AT instituteofmedicineusxxbforumondrugdiscoverydevelopmentandtranslation breakthroughbusinessmodelsdrugdevelopmentforrareandneglecteddiseasesandindividualizedtherapiesworkshopsummary |